Taipei + 886.2.7712.3245

Barry Lai's practice is focused primarily on intellectual property, with an emphasis on patent litigation and intellectual property contractual disputes. He has experience in high-stakes patent infringement cases involving a variety of technologies, including software, LED backlight driver products, voltage converter circuits, and electronic component inspection equipment. Barry also advises national and multinational clients on product liability and information technology (IT) policies.

In addition, Barry has significant knowledge in U.S. patent administrative revocation proceedings, such as post-grant reviews (PGRs), inter partes reviews, and ex parte reexaminations, and has published several papers on these topics. He also has experience in domestic and international patent prosecution and in providing infringement, patentability, and invalidity opinions. Barry has a bachelor's degree in communication engineering and is familiar with communication systems, networks, and electronic design automation.

In recent years, Barry's practice has expanded to include criminal, civil, and administrative lawsuits. He has obtained favorable results in the representation of national and international companies in patent, contract, and tort litigations. Barry has also defended chairmen and presidents of public and private companies in trade secret, securities exchange law, and Business Entity Accounting Act cases.

Barry is a member of the Taipei Bar Association. He is fluent in Chinese and English.


  • Ability Opto-Electronics resolves patent infringement dispute relating to computer camera lensesJones Day defended Taiwan-based Ability Opto-Electronics Technology Co., Ltd. in a patent infringement lawsuit filed by its competitor Largan Precision Co., Ltd., in a case relating to optical lens systems for cameras and computers.
  • Chroma acquires 20.5% of CamtekJones Day advised Chroma ATE Inc., a leading Taiwanese corporation, in its acquisition of approximately 20.5% of the shares of Camtek Ltd. at $9.50 per share.
  • Speaking Engagements

    • May 27, 2018
      企業的法律風險管理, 政大EMBA課程
    • May 11, 2018
      營業秘密法, 大樹醫藥股份有限公司董事會